ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/complete-estrogen-receptor-antagonist
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/complete-estrogen-receptor-antagonist
3
trial(s) found.
NCT07085767
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (
OPERA-02
)
CDK4/6 inhibitor
aromatase inhibitor
complete estrogen receptor antagonist
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06784193
Advanced
Phase 1
Recruiting
A Phase 1 First-in-Human, Open-Label, Multicenter Study of OP-3136 in Adult Participants With Advanced or Metastatic Solid Tumors (
OP-3136-101
)
KAT6A/B inhibitor
KAT6 inhibitor
+ complete estrogen receptor antagonist
Breast cancer
Castrate-resistant prostate cancer
Non-small cell lung cancer
Prostate cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05508906
Advanced
Phase 1
Recruiting
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer (
OP-1250-003
)
CDK4/6 inhibitor
CDK4 selective inhibitor
PI3K alpha inhibitor
complete estrogen receptor antagonist
mTORC1 inhibitor
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
NSW (2)
SA (2)
WA (2)
QLD (1)
VIC (1)
Phase
Phase 1 (2)
Phase 3 (1)
Trial Type
Advanced (3)
Cancer Therapy Class
ER
100%
oestrogen axis
100%
CDK4
67%
CDK6
67%
KAT6
33%
KAT6A
33%
CDK4 selective
33%
PI3Kalpha
33%
mTOR
33%
mTORC1
33%
Facility
2109 - North Ryde - Macquarie University Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3168 - Clayton - Monash Medical Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
ER-positive breast cancer
HER2-negative breast cancer
HR-positive breast cancer
Castrate-resistant prostate cancer
Lung cancer
Male genital cancers
Non-small cell lung cancer
Prostate adenocarcinoma
Prostate cancer
Respiratory tract cancer
Thoracic cancer
Urogenital cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy